A Phase 2 interventional study of Insulin lispro and recombinant human hyaluronidase PH20 in Diabetes Mellitus, Type 1, sponsored by Halozyme Therapeutics. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Halozyme Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 10th largest by enrollment, is one of 4 that started in 2010, is one of 7 in phase 2, and was the 15th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2002; this study’s year is marked. 4 started in 2010.
This study's enrollment of 135 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 69 interventional studies. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 69 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing Insulin Lispro in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in basal-bolus therapy.
Criteria for randomization into the study included 1) fasting blood glucose and predinner glucose values in the range of 70 to 140 milligrams per deciliter (mg/dL) approximately 60% of the time for 7 days prior to randomization 2) 90 minute or 2-hour postprandial blood glucose \<220 mg/dL approximately 70% of the time for 7 days prior to randomization and 3) successfully completed 3 days of 10-point glucose monitoring and have at least 4 self-monitored blood glucose values on all non-10-point monitoring days. Participants that did not meet 1 or more of these criteria during a 4- to 6-week Titration Period were not randomized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually. Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period. Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine.
Drug: Insulin lispro · Drug: recombinant human hyaluronidase PH20 · Drug: Insulin glulisine · Drug: Insulin glargine
All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually. Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period. Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine.
Drug: Insulin lispro · Drug: recombinant human hyaluronidase PH20 · Drug: Insulin aspart · Drug: Insulin glulisine · Drug: Insulin glargine
Also known as: Humalog
Also known as: Hylenex, rHuPH20, PH20
Also known as: Apidra
Also known as: Lantus
Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period
Glycosylated hemoglobin A1C (HBA1c) levels were measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). Least Squares (LS) means were calculated from mixed effects linear models with treatment (Lispro, Aspart), recombinant human hyaluronidase PH20 (rHuPH20; yes, no), and treatment sequence as fixed effects and participant within treatment sequence as a random effect.
Time frame: Baseline, Week 12 and Week 24
Mean Daily Insulin Dose
Prandial insulin doses were recorded during 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). The mean daily insulin dose over the 3 days during each treatment period is presented. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).
Time frame: Week 10 and Week 22
Percentage of Participants Meeting Glucose Targets
Participants were instructed to monitor their blood glucose levels a minimum of 4 times per day on all non-10-point glucose monitoring days. The number of participants meeting 90-minute postprandial plasma glucose (PPG) targets of \<140 and \<180 milligrams per deciliter (mg/dL) for at least 2/3 of values during non-10-point glucose monitoring days was recorded. The percentage was calculated by dividing the number of participants with values meeting the specified target at least 2/3 of the time by the total number of participants analyzed, multiplied by 100. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).
Time frame: Baseline through Week 24, excluding 10-point glucose monitoring days
Rates of Hypoglycemia at the End of Each Treatment Period
Overall rates of hypoglycemia (blood glucose ≤70 milligrams per deciliter \[mg/dL\] and \<56 mg/dL) were calculated based on 4 weeks of observation for each treatment period. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Week 12 and Week 24
Change From Baseline in Body Weight at the End of Each Treatment Period
Body weight was measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).
Time frame: Baseline, Week 12 and Week 24
Mean Daily Postprandial Glucose (PPG) Excursions
Participants performed 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). Mean daily postprandial plasma glucose (PPG) excursions (referring to the change in blood glucose levels from before to after a meal) during 10-point glucose monitoring for breakfast, lunch, and dinner are presented. Data were collected 1 and 2 hours (hr) after each meal for 3 days and the means of each excursion are presented.
Time frame: Week 10 and Week 22
| Milestone | All Enrolled Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 |
|---|---|---|---|---|---|
| Started | 135 | 0 | 0 | 0 | 0 |
| Completed | 117 | 0 | 0 | 0 | 0 |
| Not completed | 18 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Titration failure | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet randomization criteria | 7 | 0 | 0 | 0 | 0 |
| Milestone | All Enrolled Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 |
|---|---|---|---|---|---|
| Started | 0 | 29 | 28 | 30 | 30 |
| Received at least 1 dose of study drug | 0 | 29 | 28 | 30 | 30 |
| Completed | 0 | 29 | 27 | 29 | 28 |
| Not completed | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 1 |
| Milestone | All Enrolled Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 |
|---|---|---|---|---|---|
| Started | 0 | 29 | 27 | 29 | 28 |
| Completed | 0 | 29 | 27 | 29 | 28 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Prandial insulin doses were recorded during 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). The mean daily insulin dose over the 3 days during each treatment period is presented. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).
| units (U) | Analog-PH20 | Insulin Lispro |
|---|---|---|
| Mean Daily Insulin Dose | 54.28 ± 27.071 | 56.05 ± 27.243 |
Participants were instructed to monitor their blood glucose levels a minimum of 4 times per day on all non-10-point glucose monitoring days. The number of participants meeting 90-minute postprandial plasma glucose (PPG) targets of \<140 and \<180 milligrams per deciliter (mg/dL) for at least 2/3 of values during non-10-point glucose monitoring days was recorded. The percentage was calculated by dividing the number of participants with values meeting the specified target at least 2/3 of the time by the total number of participants analyzed, multiplied by 100. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).
| percentage of participants | Analog-PH20 | Insulin Lispro |
|---|---|---|
| PPG <140 mg/dL for all meals | 15.0 | 8.8 |
| PPG <140 mg/dL for breakfast | 21.4 | 10.6 |
| PPG <180 mg/dL for all meals | 69.9 | 59.3 |
| PPG <180 mg/dL for breakfast | 70.5 | 54.0 |
Overall rates of hypoglycemia (blood glucose ≤70 milligrams per deciliter \[mg/dL\] and \<56 mg/dL) were calculated based on 4 weeks of observation for each treatment period. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per month | Analog-PH20 | Insulin Lispro |
|---|---|---|
| ≤70 mg/dL | 18.96 | 19.91 |
| <56 mg/dL | 7.50 | 8.05 |
Glycosylated hemoglobin A1C (HBA1c) levels were measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). Least Squares (LS) means were calculated from mixed effects linear models with treatment (Lispro, Aspart), recombinant human hyaluronidase PH20 (rHuPH20; yes, no), and treatment sequence as fixed effects and participant within treatment sequence as a random effect.
| percentage of hemoglobin A1C | Analog-PH20 | Insulin Lispro |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period | -0.14 ± 0.415 | -0.19 ± 0.440 |
Body weight was measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).
| pounds (lbs) | Analog-PH20 | Insulin Lispro |
|---|---|---|
| Change From Baseline in Body Weight at the End of Each Treatment Period | -0.25 ± 5.702 | 0.10 ± 4.601 |
Participants performed 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). Mean daily postprandial plasma glucose (PPG) excursions (referring to the change in blood glucose levels from before to after a meal) during 10-point glucose monitoring for breakfast, lunch, and dinner are presented. Data were collected 1 and 2 hours (hr) after each meal for 3 days and the means of each excursion are presented.
| milligrams per deciliter (mg/dL) | Analog-PH20 | Insulin Lispro |
|---|---|---|
| 1-hr breakfast excursion | 18.85 ± 48.348 | 27.46 ± 43.938 |
| 2-hr breakfast excursion | -5.63 ± 52.657 | 7.08 ± 56.997 |
| 1-hr lunch excursion | 16.26 ± 46.524 | 26.25 ± 39.070 |
| 2-hr lunch excursion | 10.68 ± 53.787 | 20.77 ± 47.005 |
| 1-hr dinner excursion | -0.31 ± 41.368 | 4.47 ± 52.986 |
| 2-hr dinner excursion | -5.13 ± 46.956 | -5.16 ± 54.309 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Titration Period (All Enrolled Participants) | — | 2/135 (1.5%) | 48/135 (35.6%) |
| Lispro-PH20 Treatment Period | — | 0/56 (0%) | 34/56 (60.7%) |
| Insulin Lispro (Lispro-PH20 Cohort) Treatment Period | — | 1/57 (1.8%) | 29/57 (50.9%) |
| Aspart-PH20 Treatment Period | — | 0/58 (0%) | 27/58 (46.6%) |
| Insulin Lispro (Aspart-PH20 Cohort) Treatment Period | — | 1/59 (1.7%) | 30/59 (50.8%) |
| Event | Titration Period (All Enrolled Participants) | Lispro-PH20 Treatment Period | Insulin Lispro (Lispro-PH20 Cohort) Treatment Period | Aspart-PH20 Treatment Period | Insulin Lispro (Aspart-PH20 Cohort) Treatment Period |
|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 1/135 | 0/56 | 1/57 | 0/58 | 1/59 |
| PericarditisCardiac disorders | 1/135 | 0/56 | 0/57 | 0/58 | 0/59 |
| Event | Titration Period (All Enrolled Participants) | Lispro-PH20 Treatment Period | Insulin Lispro (Lispro-PH20 Cohort) Treatment Period | Aspart-PH20 Treatment Period | Insulin Lispro (Aspart-PH20 Cohort) Treatment Period |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/135 | 8/56 | 8/57 | 8/58 | 6/59 |
| Upper respiratory tract infectionInfections and infestations | 8/135 | 7/56 | 3/57 | 2/58 | 3/59 |
| SinusitisInfections and infestations | 5/135 | 2/56 | 3/57 | 5/58 | 2/59 |
| HeadacheNervous system disorders | 2/135 | 1/56 | 1/57 | 4/58 | 1/59 |
| PyrexiaGeneral disorders | 2/135 | 1/56 | 3/57 | 0/58 | 0/59 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/135 | 0/56 | 0/57 | 3/58 | 0/59 |
| Gastroenteritis viralInfections and infestations | 1/135 | 1/56 | 2/57 | 2/58 | 3/59 |
| NauseaGastrointestinal disorders | 2/135 | 1/56 | 0/57 | 1/58 | 3/59 |
| DysmenorrhoeaReproductive system and breast disorders | 0/61 | 0/26 | 1/26 | 0/28 | 0/29 |
| Back painMusculoskeletal and connective tissue disorders | 2/135 | 2/56 | 0/57 | 0/58 | 0/59 |
All enrolled participants.
| Age, Continuous(years) | Non-randomized Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 | Total |
|---|---|---|---|---|---|---|
| Mean | 34.8 ± 11.71 | 44.6 ± 14.56 | 45.7 ± 14.94 | 42.8 ± 14.13 | 42.5 ± 14.70 | 42.6 ± 14.41 |
| Sex: Female, Male(Participants) | Non-randomized Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 13 | 13 | 14 | 15 | 61 |
| Male | 12 | 16 | 15 | 16 | 15 | 74 |
| Race (NIH/OMB)(Participants) | Non-randomized Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 2 | 3 |
| White | 17 | 27 | 27 | 30 | 28 | 129 |
| More than one race | 0 | 2 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Non-randomized Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 2 | 2 | 1 | 10 |
| Not Hispanic or Latino | 14 | 28 | 26 | 28 | 29 | 125 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Non-randomized Participants | Lispro-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Lispro-PH20 | Aspart-PH20 First, Then Insulin Lispro | Insulin Lispro First, Then Aspart-PH20 | Total |
|---|---|---|---|---|---|---|
| United States | 18 | 29 | 28 | 30 | 30 | 135 |
The record gives a start of Aug 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Hyaluronidase (human recombinant)